Clinical and epidemiological implications of meningococcal disease

Journal of Association of Physicians of India

Volumn 53, Issue JUL, 2005, Pages 628-633

  Meredith, J R ^a   Galwankar, S ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; DISEASE COURSE; EPIDEMIC; HUMAN; INDIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENICITY; PATHOLOGY; REVIEW; RISK FACTOR; SEASON;

ANTIBIOTIC PROPHYLAXIS; DISEASE OUTBREAKS; DISEASE PROGRESSION; HUMANS; INDIA; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RISK FACTORS; SEASONS;

EID: 24644436378     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Centers for Disease Control and Prevention (CDC). Meningococcal Disease. Available at http://www.cdc.gov/ ncidod/dbmd/diseaseinfo/meningococcal_g.htm. Accessed on May 5, 2005.
2. World Health Organization (WHO). Communicable Disease Surveillance and Response. Available at http:// www.who.int/csr/disease/meningococcal/en/index. html. Accessed on May 5, 2005.
3. Singh J, Arrieta AC. Management of meningococcemia. Ind J Pediatr 2004;71:909-13.
4. Ferguson LE, Hormann MD, Parks DK, Yetman RJ. Neisseria meningitidis: Presentation, treatment, and prevention. J Pediatr Health Care 2002;16:119-24.
5. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:1849-59.
6. rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. p. 980-4.
7. Harris NJ, Gosh M. Skin and extremity loss in meningococcal septicemia treated in a burn unit. Burns 1994;20:471-2.
8. Fischer M, Hilinski J, Stephens DS. Adjuvant therapy for meningococcal sepsis. Pediatr Infect Dis J 2005;24:177-8.
9. Overturf GD. Indications for the immunologic evaluation of patients with meningitis. Clin Infect Dis 2003;36:189-94.
10. Pinner RW, Onyano F, Perkins BA, Mirza NB, Ngacha DM, Reeves M, et al. Epidemic meningococcal diseases in Nairobi, Kenya, 1989. J Infect Dis 1992;166:359-64.
11. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Int Med 1995;123:937-40.
12. Peltola H, Makela PH, Kayhty H, Jousimie H, Herva E, Hallstrom K, et al. Clinical efficacy of meningococcus group A polysaccharide vaccine in children three months to five years of age. N Eng J Med 1977;297:686-91.
13. Hazelnet JA. Diagnosing meningococcemia as a cause of sepsis. Pediatr Crit Care Med 2005;6(3)(Suppl 50-54).
14. Broome CV. Carrier state: Neisseria meningitidis. J Antimicrob Chemother 1986;18:25-34.
15. th ed. New York, NY: McGraw-Hill; 2001. p. 51-63.
16. Schaad UB, abdus Salam MA, Aujard Y, Dagan R, Green SD, Peltola H, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
17. Judson FN, Ehret JM. Single-dose ceftriaxone to eradicate pharyngeal Neisseria meningitidis. Lancet 1984:2;1462-3.
18. Salzman MB. Meningococcemia. Infect Dis Clin North Am 1996;10:709-25.
19. th ed. Philadelphia, PA: W.B. Saunders Company; 1998. p. 1143-54.
20. th ed. Philadelphia, PA: W.B. Saunders Company; 2000. p. 826-9.
21. Mehta N, Levin M. Management and prevention of meningococcal disease. Hospital Practice 2000;35:75-81.
22. American Academy of Pediatrics. Meningococcal disease prevention and control strategies for practice-based physicians. Pediatrics 1996;97:404-12.
23. th ed. St. Louis, MO: Mosby; 2002. p. 1802.